About

Genetic and acquired neuromuscular diseases represent a major cause of mortality and morbidity in children and adults with a prevalence of more than 5% in the general population. Currently there is a large gap between major basic science discoveries and patient benefit in these important disorders. In order to reduce this gap we form the first truly multidisciplinary translational research centre into these disabling diseases.

Our mission is to translate basic science findings into clinical trials and new treatments for children and adults with disabling neuromuscular diseases.

The centre is based at the UCL Institute of Neurology in collaboration with the UCL Institute of Child Health, other departments of UCL and at the University of Newcastle Upon Tyne. There is a very large adult and paediatric patient populations with neuromuscular diseases cared for at the co-located hospitals: The National Hospital for Neurology and Neurosurgery, UCLH Foundation Trust; Great Ormond Street NHS Trust, and the Newcastle teaching hospitals.

National Hospital for Neurology and NeurosurgeryInstitute of Child HealthCentre for Life, Newcastle

News

UK Neuromuscular Translational Research Conference 2010
The MRC Centre for Neuromuscular Diseases and the Muscular Dystrophy Campaign are pleased to announce that the 2010 meeting will take place Thursday 25th - Friday 26th March 2010 in Oxford.

Update in Neuromuscular Disorders 2010
This year's joint paediatric and adult course will run from Monday 24th - Thursday 27th May 2010 inclusive at Queen Square.

NIH Grant for research into inherited neuropathies
1st October 2009
Dr Mary Reilly (MRC Centre for Neuromuscular Diseases, Department of Molecular Neurosciences, UCL Institute of Neurology) and Professor Michael Shy, (Wayne State University, USA) together with four other US collaborators have just been awarded a $6.25 million grant from the NIH Rare Diseases Clinical Research Network to fund research into Charcot-Marie Tooth disease.Drug discovery collaboration on inclusion body myositis
The MRC Centre for Neuromuscular Diseases, Senexis Limited, and the Oxford MRC Functional Genomics Unit (FGU) have announced that they have agreed to collaborate on the discovery of novel therapeutics for Inclusion Body Myositis (IBM).

British Myology Society Annual Meeting
The second annual meeting of the BMS will take place on 2nd - 3rd September 2010 at St Anne's College, Oxford.

News Archive

logos
© 2008 Centre for Neuromuscular Diseases